Celadon Pharmaceuticals PLC
LSE:CEL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Income Statement
Earnings Waterfall
Celadon Pharmaceuticals PLC
Income Statement
Celadon Pharmaceuticals PLC
| Feb-2021 | Aug-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
0
|
0
|
0
|
4
|
4
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
+465%
|
1
+10 502%
|
0
-98%
|
371
+1 793 166%
|
0
-100%
|
37
+28 603%
|
37
-2%
|
37
+2%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
0
|
0
|
(2)
|
(2)
|
(5)
|
(6)
|
(5)
|
(5)
|
0
|
0
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
(2)
N/A
|
(2)
+24%
|
(5)
-171%
|
(6)
-23%
|
(5)
+11%
|
(4)
+17%
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(0)
|
(0)
|
(0)
|
(1)
|
(668)
|
(1)
|
(588)
|
(1)
|
(504)
|
(252)
|
(384)
|
|
| Selling, General & Administrative |
(0)
|
(0)
|
0
|
0
|
(213)
|
0
|
(206)
|
0
|
(183)
|
(95)
|
(159)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
(462)
|
0
|
(387)
|
0
|
(321)
|
(155)
|
(225)
|
|
| Depreciation & Amortization |
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
7
|
0
|
7
|
0
|
0
|
(2)
|
0
|
|
| Operating Income |
(0)
N/A
|
(0)
-120%
|
(3)
-471%
|
(3)
+5%
|
(672)
-25 956%
|
(7)
+99%
|
(222)
-3 267%
|
(5)
+98%
|
(467)
-9 207%
|
(215)
+54%
|
(346)
-61%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
0
|
0
|
(1)
|
(4)
|
(4)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
(0)
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
(96)
|
|
| Total Other Income |
0
|
0
|
0
|
(6)
|
27
|
(1)
|
72
|
0
|
104
|
41
|
64
|
|
| Pre-Tax Income |
(0)
N/A
|
(0)
-55%
|
(5)
-914%
|
(14)
-191%
|
(651)
-4 559%
|
(9)
+99%
|
(151)
-1 557%
|
(5)
+96%
|
(363)
-6 502%
|
(174)
+52%
|
(379)
-118%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
1
|
(3)
|
0
|
(4)
|
(2)
|
(3)
|
|
| Income from Continuing Operations |
(0)
|
(0)
|
(5)
|
(14)
|
(650)
|
(8)
|
(154)
|
(5)
|
(366)
|
(176)
|
(382)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(0)
N/A
|
(0)
-55%
|
(5)
-878%
|
(14)
-197%
|
(650)
-4 629%
|
(8)
+99%
|
(154)
-1 806%
|
(5)
+97%
|
(366)
-6 900%
|
(176)
+52%
|
(382)
-117%
|
|
| EPS (Diluted) |
-0.05
N/A
|
-0.06
-20%
|
-0.1
-67%
|
-0.26
-160%
|
-8.36
-3 115%
|
-0.13
+98%
|
-1.94
-1 392%
|
-0.08
+96%
|
-4.34
-5 325%
|
-2.06
+53%
|
-4.38
-113%
|
|
